One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer

Bent Ejlertsen; Maj-Britt Jensen; Johanna Elversang; Birgitte B Rasmussen; Michael Andersson; Jørn Andersen; Dorte L Nielsen; Søren Cold; Henning T Mouridsen

doi:10.1016/j.ejca.2013.05.006

One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer

Bent Ejlertsen, Maj-Britt Jensen, Johanna Elversang, Birgitte B Rasmussen, Michael Andersson, Jørn Andersen, Dorte L Nielsen, Søren Cold, Henning T Mouridsen

8 Citations (Scopus)

Abstract

We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients. In addition, we analyse the prognostic and predictive value of centrally assessed subtypes.

Original language	English
Journal	European journal of cancer (Oxford, England : 1990)
Volume	49
Issue number	14
Pages (from-to)	2986-94
Number of pages	9
ISSN	0959-8049
DOIs	https://doi.org/10.1016/j.ejca.2013.05.006
Publication status	Published - Sept 2013

Access to Document

10.1016/j.ejca.2013.05.006

Cite this

Ejlertsen, B., Jensen, M.-B., Elversang, J., Rasmussen, B. B., Andersson, M., Andersen, J., Nielsen, D. L., Cold, S., & Mouridsen, H. T. (2013). One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. European journal of cancer (Oxford, England : 1990), 49(14), 2986-94. https://doi.org/10.1016/j.ejca.2013.05.006

One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. / Ejlertsen, Bent ; Jensen, Maj-Britt; Elversang, Johanna et al.
In: European journal of cancer (Oxford, England : 1990), Vol. 49, No. 14, 09.2013, p. 2986-94.

Research output: Contribution to journal › Journal article › Research › peer-review

Ejlertsen, B , Jensen, M-B, Elversang, J, Rasmussen, BB, Andersson, M, Andersen, J, Nielsen, DL, Cold, S & Mouridsen, HT 2013, 'One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer', European journal of cancer (Oxford, England : 1990), vol. 49, no. 14, pp. 2986-94. https://doi.org/10.1016/j.ejca.2013.05.006

@article{f593f36f0f4542baa17c31fa13c944de,

title = "One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer",

abstract = "We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients. In addition, we analyse the prognostic and predictive value of centrally assessed subtypes.",

author = "Bent Ejlertsen and Maj-Britt Jensen and Johanna Elversang and Rasmussen, \{Birgitte B\} and Michael Andersson and J{\o}rn Andersen and Nielsen, \{Dorte L\} and S{\o}ren Cold and Mouridsen, \{Henning T\}",

year = "2013",

month = sep,

doi = "10.1016/j.ejca.2013.05.006",

language = "English",

volume = "49",

pages = "2986--94",

journal = "European journal of cancer (Oxford, England : 1990)",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "14",

}

TY - JOUR

T1 - One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer

AU - Ejlertsen, Bent

AU - Jensen, Maj-Britt

AU - Elversang, Johanna

AU - Rasmussen, Birgitte B

AU - Andersson, Michael

AU - Andersen, Jørn

AU - Nielsen, Dorte L

AU - Cold, Søren

AU - Mouridsen, Henning T

PY - 2013/9

Y1 - 2013/9

N2 - We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients. In addition, we analyse the prognostic and predictive value of centrally assessed subtypes.

AB - We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients. In addition, we analyse the prognostic and predictive value of centrally assessed subtypes.

UR - https://www.scopus.com/pages/publications/84883055437

U2 - 10.1016/j.ejca.2013.05.006

DO - 10.1016/j.ejca.2013.05.006

M3 - Journal article

C2 - 23756360

SN - 0959-8049

VL - 49

SP - 2986

EP - 2994

JO - European journal of cancer (Oxford, England : 1990)

JF - European journal of cancer (Oxford, England : 1990)

IS - 14

ER -

One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer

Abstract

Access to Document

Other files and links

Fingerprint

Cite this